Avastin Approval History
FDA Approved: Yes (First approved February 26, 2004)
Brand name: Avastin
Generic name: bevacizumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, and peritoneal cancer.
Development History and FDA Approval Process for Avastin
|Jun 13, 2018|| FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery|
|Dec 5, 2017|| FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer|
|Dec 6, 2016|| FDA Approves Avastin (bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer|
|Nov 14, 2014|| FDA Approves Avastin (bevacizumab) Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer |
|Aug 14, 2014|| FDA Approves Avastin for Metastatic Cervical Cancer|
|Nov 18, 2011|| FDA Revokes Breast Cancer Indication for Avastin (bevacizumab)|
|Aug 3, 2009|| FDA Approves Avastin for the Most Common Type of Kidney Cancer|
|May 6, 2009|| FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy|
|Feb 25, 2008|| FDA Grants Accelerated Approval of Avastin in Combination With
Paclitaxel Chemotherapy for First-Line Treatment of Advanced
HER2-Negative Breast Cancer|
|Oct 11, 2006|| FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer|
|Apr 12, 2006||Avastin Filed in US for Treatment of Most Common Form of Lung Cancer|
|Feb 26, 2004|| Avastin Approved for treatment for Metastatic Colorectal Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.